DeutschNewstral
Article
Mmarketwatch.com on 2019-10-22 13:12
Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process
Related news
FDA approval of Biogen's Alzheimer's drug leaves some 'disappointed'Fox News- MFDA calls for investigation into its own approval of Biogen's Alzheimer's drug2 min readmarketwatch.com
Biogen's Alzheimer's drug wins FDA approvalbizjournals.com- MBiogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surgesmarketwatch.com
- For Alzheimer's patient advocates, Biogen's drug approval opens the doorbizjournals.com
- MBiogen's stock soars after positive results from study of Alzheimer's treatmentmarketwatch.com
- MBiogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatmentmarketwatch.com
- MBiogen's stock rallies 11% after FDA accepts application for experimental Alzheimer's drugmarketwatch.com
- BFDA Narrows Its Label on Biogen's Alzheimer's Drug a Month After Approving It3 min readbarrons.com
- BThe FDA Decision on Biogen's Alzheimer's Drug Is Almost Here. What Investors Need to Know.barrons.com
- MBiogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says3 min readmarketwatch.com
- Biogen's drug approval in Alzheimer's spurs two FDA advisers to resignbizjournals.com
The F.D.A.'s Approval of Biogen's Alzheimer's Drug Is a New LowThe New York Times- BTop FDA Staffers Defend Approval of Biogen's Alzheimer's Drug 4 min readbarrons.com
Biogen's Alzheimer's drug slows mental declineReuters
Study: Biogen's Alzheimer's drug slows mental declineHaaretz- Medicare severely restricts Biogen's Alzheimer's drug coveragebizjournals.com
- MBiogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drug2 min readmarketwatch.com
- BThe $56,000 Price of Biogen's Alzheimer's Drug Could Backfire4 minbarrons.com